These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25715382)

  • 1. Medications used in the treatment of disruptive behavior in children with FASD--a guide.
    Ozsarfati J; Koren G
    J Popul Ther Clin Pharmacol; 2015; 22(1):e59-67. PubMed ID: 25715382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A symposium on Attention Deficit Hyperactivity Disorder (ADHD). Developments in treatment.
    Levy F
    Aust N Z J Psychiatry; 2002 Aug; 36(4):477-9. PubMed ID: 12169142
    [No Abstract]   [Full Text] [Related]  

  • 4. [Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
    Rothermel B; Poustka L; Banaschewski T; Becker K
    Z Kinder Jugendpsychiatr Psychother; 2010 Mar; 38(2):123-9; quiz 130. PubMed ID: 20200829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness and Tolerability of Central Nervous System Stimulants in School-Age Children with Attention-Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Across Home and School.
    Baweja R; Belin PJ; Humphrey HH; Babocsai L; Pariseau ME; Waschbusch DA; Hoffman MT; Akinnusi OO; Haak JL; Pelham WE; Waxmonsky JG
    J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):154-63. PubMed ID: 26771437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship between Acute Dyskinesia with a Single Dose of Methylphenidate and Recent Risperidone Discontinuation in a Child with Attention-Deficit/Hyperactivity Disorder.
    Ince E; Algedik P; Demirdogen ES; Emul M; Demir T
    J Child Adolesc Psychopharmacol; 2015 May; 25(4):378-9. PubMed ID: 25920038
    [No Abstract]   [Full Text] [Related]  

  • 8. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
    Joseph HM; Farmer C; Kipp H; Kolko D; Aman M; McGinley J; Arnold LE; Gadow KD; Findling RL; Molina BSG
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):90-99. PubMed ID: 30592635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemoline in ADHD.
    Winsberg B; Barbato M
    J Am Acad Child Adolesc Psychiatry; 1997 Dec; 36(12):1649-50. PubMed ID: 9401321
    [No Abstract]   [Full Text] [Related]  

  • 11. The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Storebø OJ; Faltinsen E; Zwi M; Simonsen E; Gluud C
    Clin Pharmacol Ther; 2018 Oct; 104(4):606-609. PubMed ID: 30006934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.
    Froehlich TE; Fogler J; Barbaresi WJ; Elsayed NA; Evans SW; Chan E
    Clin Pharmacol Ther; 2018 Oct; 104(4):619-637. PubMed ID: 30053315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-handicapping prior to academic-oriented tasks in children with attention deficit/hyperactivity disorder (ADHD): medication effects and comparisons with controls.
    Waschbusch DA; Craig R; Pelham WE; King S
    J Abnorm Child Psychol; 2007 Apr; 35(2):275-86. PubMed ID: 17195950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulants, neuroleptics, and children's friendship training for children with fetal alcohol spectrum disorders.
    Frankel F; Paley B; Marquardt R; O'Connor M
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):777-89. PubMed ID: 17201621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
    Elbe D; Barr AM; Honer WG; Procyshyn RM
    J Psychiatry Neurosci; 2014 May; 39(3):E32-3. PubMed ID: 24758945
    [No Abstract]   [Full Text] [Related]  

  • 16. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder.
    Gorman DA; Gardner DM; Murphy AL; Feldman M; Bélanger SA; Steele MM; Boylan K; Cochrane-Brink K; Goldade R; Soper PR; Ustina J; Pringsheim T
    Can J Psychiatry; 2015 Feb; 60(2):62-76. PubMed ID: 25886657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone in comorbid ADHD and ODD/CD.
    Kewley GD
    J Am Acad Child Adolesc Psychiatry; 1999 Nov; 38(11):1327-8. PubMed ID: 10560215
    [No Abstract]   [Full Text] [Related]  

  • 18. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality.
    Penzner JB; Dudas M; Saito E; Olshanskiy V; Parikh UH; Kapoor S; Chekuri R; Gadaleta D; Avedon J; Sheridan EM; Randell J; Malhotra AK; Kane JM; Correll CU
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):563-73. PubMed ID: 19877981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
    Magalotti SR; Neudecker M; Zaraa SG; McVoy MK
    Curr Psychiatry Rep; 2019 Nov; 21(12):123. PubMed ID: 31741142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.